• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Consumer Cyclical·301009.SZ
Share

Hangzhou Coco Healthcare Products Co.,Ltd. Stocks

CN¥ 9.22Last Updated 12.10.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

CN¥ 368.66M

CN¥ 9.22
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Hangzhou Coco Healthcare Products Co.,Ltd. is a Chinese enterprise dedicated to the innovation, manufacturing, and distribution of products across three main categories: baby care, adult incontinence, and pet hygiene. Its extensive portfolio of adult incontinence solutions features items such as adult diapers, pull-up pants, nursing pads, maternity towels, and menstrual pants, alongside a variety of general absorbent towels and specialized absorbent pads for men. Established in 2001, the company was initially known as Hangzhou Qiaozi Paper Industry Co.,Ltd. before adopting its current name, Hangzhou Coco Healthcare Products Co.,Ltd., in December 2011. Its operations are based in Hangzhou, China.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.10.2026 18:03

Shares of Nebius' competitor surged following news of a contract with Anthropic

12.10.2026 17:57

China's CXMT has unsettled investors in Micron and Samsung, causing their stock prices to fall. What's going on?

12.10.2026 16:53

Jennifer Garner's company could see its stock price rise by 50%: Freedom has identified unaccounted-for growth drivers

12.10.2026 16:43

"The bar is being raised for any IPO": What signal does the cancellation of Firmus's listing send to the market?

12.10.2026 15:36

Morning in New York: Oil Caught Between De-escalation and the Risk of New Attacks

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026